What are C5a receptor antagonist drugs?

C5a receptor antagonist drugs are pharmacologic agents that share a common mechanism (typically targeting C5aR (C5a receptor)). 0 are currently marketed, with 5 more in clinical development.

C5a receptor antagonist

0 marketed 3 in Phase 3 2 in Phase 2

This page covers all C5a receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting C5aR (C5a receptor), C5aR1 (C5a receptor 1), C5a receptor (C5aR).

Targets

C5aR (C5a receptor) · C5aR1 (C5a receptor 1) · C5a receptor (C5aR)

Phase 3 pipeline (3)

HBM9036 0.25% Ophthalmic Solution · Harbour BioMed (Guangzhou) Co. Ltd. · Ophthalmology
HBM9036 is a small-molecule inhibitor of the C5a receptor that reduces complement-mediated inflammation in the eye.
EN3267 · Kyowa Kirin Co., Ltd. · Immunology
EN3267 is a complement C5a receptor antagonist that blocks the C5a-C5aR1 axis to reduce inflammatory cell recruitment and activation.
FK199B · Astellas Pharma Inc · Immunology
FK199B is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.

Phase 2 pipeline (2)

ASP4070 · Astellas Pharma Inc · Immunology
ASP4070 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.
ASP3652 · Astellas Pharma Europe B.V. · Immunology
ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.